EUCTR2012-001556-19-ES进行中（未招募）不适用
A Prospective, Randomized, Doubled-masked, Single Center, Clinical Comparison of Autologous Serum, Heterologous Serum and Umbilical Cord Serum Eye Drops in the Management of Dry Eye Syndrome - COL_SCU_2011
FUNDACION IMABIS0 个研究点开始时间: 2012年5月29日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Dry eye symptoms (red eyes, lid inflammation, discharge, dry eye, sandy and foreign body sensations, burning, itching, discomfort, pricking, tearing and photophobia) for more than three months.
- •- BUT < 5 seconds or
- •- Schirmer Test (tipe I) < 5 mm.
- •- Patients over 18 years old with severe dry eye of all etiologies.
- •- previous signment of informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 110
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 13
排除标准
- •1)Eye-infection or inflammation not related to the dry eye.
- •2)Contact lens users.
- •3)Ocular allergy in the past three months.
- •4)Eyelid and eyelashes malpositions.
- •5)Pregnant women
- •6) Positive infectious diseases (haepatitis B and C, HIV and syphilis.
- •7) Patients with problems related to blood extraction.
- •8) Patients that have in a clinical trail 30 days prior to the inclusion, in which there has been topical therapy.
- •9) Patients with chronical therapy with topical corticosteroids.
研究者
相似试验
已完成
不适用
Prospective, randomized, double-masked, multicenter post-market clinical investigation comparing two dispersive viscosurgical devicesH25Senile cataractDRKS00029292Carl Zeiss Meditec AG270
进行中（未招募）
1 期
Safety and tolerability study to evaluate PAN-90806 for the treatment of neovascular Age-Related Macular Degeneration (AMD) in Treatment-naïve participantseovascular Age-Related Macular Degeneration (AMD)MedDRA version: 20.0 Level: PT Classification code 10071129 Term: Neovascular age-related macular degeneration System Organ Class: 10015919 - Eye disordersEUCTR2016-004601-14-CZPanOptica, Inc.60
进行中（未招募）
1 期
Safety and tolerability study to evaluate PAN-90806 for the treatment of neovascular Age-Related Macular Degeneration (AMD) in Treatment-naïve participantsEUCTR2016-004601-14-GBPanOptica, Inc.51
进行中（未招募）
1 期
Safety and tolerability study to evaluate PAN-90806 for the treatment of neovascular Age-Related Macular Degeneration (AMD) in Treatment-naïve participantseovascular Age-Related Macular Degeneration (AMD)MedDRA version: 20.0 Level: PT Classification code 10071129 Term: Neovascular age-related macular degeneration System Organ Class: 10015919 - Eye disordersEUCTR2016-004601-14-HUPanOptica, Inc.60
进行中（未招募）
1 期
Safety and tolerability study to evaluate PAN-90806 for the treatment of neovascular Age-Related Macular Degeneration (AMD) in Treatment-naïve participantseovascular Age-Related Macular Degeneration (AMD)MedDRA version: 20.0 Level: PT Classification code 10071129 Term: Neovascular age-related macular degeneration System Organ Class: 10015919 - Eye disordersEUCTR2016-004601-14-LVPanOptica, Inc.60